On Monday, Shares of Aeterna Zentaris Inc. (NASDAQ:AEZS), lost -20.63% to $0.12.
Aeterna Zentaris stated a loss of $15.1 million in its second quarter, according to AP.
The Quebec City-based company said it had a loss of 14 cents per share.
The drug developer posted revenue of $197,000 in the period. AP Reports
In the final minutes of trading on Thursday, the company’s shares hit 18 cents. A year ago, they were trading at $1.19. AP added.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health.
Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA), inclined 0.59% to $69.09, during its last trading session.
Teva Pharmaceutical Industries Limited declared that the New Drug Application (NDA) for SD-809 (deutetrabenazine) has been accepted by the U.S. Food and Drug Administration (FDA) for the treatment of chorea associated with Huntington disease (HD), a rare and fatal neurodegenerative disorder caused by the progressive breakdown of nerve cells in the brain that affects about five to seven people per 100,000 in western countries, according to the World Health Organization.
The NDA filing is based on positive results from two Phase-III studies, FIRST-HD and ARC-HD. In the placebo-controlled, randomized FIRST-HD study, SD-809 reduced chorea in patients with HD. Positive top-line data from the Phase-III, open-label ARC-HD study demonstrated that patients were able to safely convert from tetrabenazine, presently the only approved HD treatment, to SD-809 overnight with continued control of chorea.
SD-809 was granted Orphan Drug Designation for the treatment of HD by the FDA in November 2014 and became part of Teva’s CNS portfolio with the acquisition of Auspex Pharmaceuticals in May 2015.
The FDA designates orphan status to drugs and biologics that are intended for the treatment of rare diseases affecting fewer than 200,000 people in the U.S.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines.
Finally, Great Plains Energy Incorporated (NYSE:GXP), ended its last trade with 0.74% gain, and closed at $27.35.
Great Plains Energy Incorporated and Kansas City Power & Light Company (KCP&L) declared the acceptance of resignation from Jim Shay, senior vice president—finance and chief financial officer. His resignation is effective September 2, 2015. Shay will be assuming the position of chief financial officer for Hallmark Cards, Inc. Shay joined Great Plains Energy and KCP&L in July 2010.
The companies also declared the promotion of Kevin Bryant to senior vice president—finance & strategy and chief financial officer of Great Plains Energy and KCP&L.
Great Plains Energy Incorporated, through its auxiliaries, generates, transmits, distributes, and sells electricity in the United States. It also provides regulated steam services in St. Joseph, Missouri. The company generates electricity using coal, nuclear, natural gas, oil, and wind resources. It has about 6,600 megawatts of generating capacity.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
